Abstract: It provides compounds of Formula I, compositions comprising the same, and methods of using the same, including use in treating various diseases and conditions, including those mediated by receptor-interacting protein 1 (RIP1) signaling.

Abstract: Disclosed in the present disclosure is a job-shop batch scheduling method based on a dueling double deep Q-network (D3QN) and a genetic algorithm. The present disclosure includes: constructing a mathematical model of a job-shop batch scheduling problem, where a goal of scheduling is to minimize a maximum completion time; determining a batch partition solution to the job-shop batch scheduling problem by the genetic algorithm; crossing and mutating chromosomes in a population; decoding the chromosomes, and obtaining a batch division solution of the workpieces to be machined; and expressing a procedure sequencing problem of the workpiece batches as a disjunctive graph model; performing representative learning on node feature information of a disjunctive graph by using a graph neural network, and extracting a feature state of the procedure sequencing problem; designing a D3QN model structure with priority experience replay, and training the D3QN model; and determining whether a termination condition is satisfied.

Abstract: Systems and methods are provided for controlling one or more optical amplifiers of a C+L band photonic line system (30) of a telecommunications network in which C-band signals and L-band signals may be transmitted. In one implementation, a method (130) may execute a traffic managing module (23). When executed, the traffic managing module (23) may be configured to enable a processing device (12) to calculate (132) a gain correction profile based on a difference between a saved baseline transmission profile (84) and a measured transmission profile (94) of a surviving band of a photonic line system (30) when another band of the photonic line system (30) is missing or impacted. The traffic managing module (23) may further be configured to enable the processing device (12) to apply (134) the gain correction profile to a respective optical amplifier (46) of the photonic line system (30) to compensate for the difference.

Abstract: Systems and methods of capacity changes in an optical network having a plurality of optical sections include, responsive to a request for a capacity change for a plurality of channels, bundling the plurality of channels into different steps such that all of the plurality of channels are assigned to a step of the different steps; and causing implementation of the different steps across the plurality of optical sections, wherein each section performs the implementation and the bundling between corresponding Optical Add/Drop Multiplexer (OADM) nodes independently and asynchronously from one another.

Abstract: Provided are azetidine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the persons health or condition.

Abstract: Systems and methods include, responsive to a request for capacity change of X channels, X is an integer >1, on an optical section (14) and at an Optical Add/Drop Multiplexer (OADM) node (12) in an optical network (10), dividing optical spectrum on the optical section into M slots, M is an integer >1, such that the capacity change of X channels takes a maximum of N steps, N is an integer >1; and performing the capacity change of X channels in up to the N steps in an interleaved manner that changes a subset of the X channels in each of the N steps. For each step, the performing can include a maximum of M/N slots of the M slots with spacing between each of the M/N slots not used for the capacity change in a corresponding step. The spacing can be f, (N+f), (2N+f), . . . , M over the optical spectrum, where f is each step, f=1, 2, . . . , N.

Abstract: A packet processing method and apparatus are provided. The method includes: on a forwarding path of an IPv6 packet, a key node (for example, a firewall) signs a packet, and a downstream apparatus of the key node verifies the signature, to determine whether the packet passes through the key node in a forwarding process. According to this application, the key node performs checking, to effectively prevent a packet which packet header is modified by attackers from bypassing the key node.

Abstract: The present disclosure discloses a method for the preparation of sulfinpyrazone, which is produced in two steps with a total yield of 48%, wherein thiophenol as the starting material is electrocatalytically coupled with dichloroethane to obtain 2-chloroethyl phenyl sulfoxide, which then undergoes a substitution reaction with 1,2-diphenyl-3,5-pyrazolidinedione to produce sulfinpyrazone. Compared with the prior art, the present method is characterized by high yield, short steps, less three wastes, good chemical selectivity, no need to use strong bases and oxidants, safe and simple operation, and easy to realize industrial production.

Abstract: A gel electrophoresis system includes a base module and a camera module. The base module includes a cassette slot for receiving a gel electrophoresis cassette, and a light element that functions to illuminate the gel electrophoresis cassette. The camera module is selectively attachable to and detachable from the base module. When attached to the base module, the camera module facilitates imaging of the gel electrophoresis cassette and provides additional imaging capabilities.

Abstract: Provided are piperazine cyclic urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), pharmaceutically acceptable salts, hydrates and stereoisomers thereof. Provided are also pharmaceutical compositions, methods of making, and methods of use which include treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: The present disclosure provides compounds including piperazine heterocyclic amide urea compounds that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrates and stereoisomers thereof. The compounds are employed in pharmaceutical compositions, and methods of making and use, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

Abstract: Provided are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Abstract: Systems and methods are provided for controlling one or more optical amplifiers of a C+L band photonic line system (30) of a telecommunications network in which C-band signals and L-band signals may be transmitted. In one implementation, a method (130) may execute a traffic managing module (23). When executed, the traffic managing module (23) may be configured to enable a processing device (12) to calculate (132) a gain correction profile based on a difference between a saved baseline transmission profile (84) and a measured transmission profile (94) of a surviving band of a photonic line system (30) when another band of the photonic line system (30) is missing or impacted. The traffic managing module (23) may further be configured to enable the processing device (12) to apply (134) the gain correction profile to a respective optical amplifier (46) of the photonic line system (30) to compensate for the difference.

Abstract: Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

Abstract: The application describes fused heterocycle derivative compounds, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment of diseases associated with HBV infection.

Abstract: The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Abstract: Provided herein are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.

Abstract: Provided herein are dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.